this company (share price) is depressing; the half yearly numbers will be interesting; the sales of product (on the up) are minor compared to the monies they take in from services; the only note I saw from the services side was they are having good success at contracts; but, I think it is possible the monies coming in from services can dip without any fanfare
obviously, the future is the product side; I hope that rockets to a major part of the business revenues
Ann: Lumos Provides ViraDx and FebriDx Regulatory Update, page-2
Add to My Watchlist
What is My Watchlist?
